The blue scorpion, a unique arachnid found exclusively in Cuba, has recently captured the attention of scientists due to the discovery of specific molecules within its venom that could potentially treat certain forms of cancer.
For over two decades, many Cuban doctors have been treating their cancer patients with blue scorpion (Rhopalurus junceus) venom, renowned for its analgesic and anti-inflammatory properties. While results vary from patient to patient, many report reduced pain and increased energy levels.
The blue scorpion (Heteroctenus junceus) is a nocturnal species belonging to the Buthidae family and is endemic to Cuba, where it primarily inhabits dry, rocky areas. Like most scorpions, its body is divided into three sections: the cephalothorax (head and legs), the abdomen (central part), and the metasoma (tail).
Despite its name, the Heteroctenus junceus is not as blue as one might think. Depending on its age and environment, its coloration can range from brown, reddish, or orange, with grayish or bluish hues.
Due to its bioactive components (peptides, toxins, and proteins), blue scorpion venom possesses various properties that have piqued the interest of researchers, particularly for its potential medical applications. These include analgesic and anti-inflammatory effects, combined with potential anticancer properties.
Preliminary studies have suggested that the venom of this Cuban scorpion species may exhibit a cytotoxic effect on certain cancer cells, including those of lung, brain, breast, and colon cancer. The venom also appears to spare healthy cells, making it a promising candidate for the development of alternative cancer treatments.
The state-owned pharmaceutical laboratory Labiofam, based in Havana, is preparing to launch a homeopathic version of the drug and aims to flood the global market. Currently, only a few countries, including China, have authorized the commercialization of this venom-based treatment.